SCYX

SCYNEXIS, Inc. Common Stock (SCYX) | Rumor.io

SCYNEXIS

SCYX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,996

Bullish sentiment (50-day avg)87%

Price to earnings ratio0.9

Market capitalization46M

Earnings per share-0.91

Dividend yield (TTM)—

Revenue (annual)20.6M

Net income (annual)-8.6M

Social

What share of all stock conversation is about SCYX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.02	0% +0	0% +0	0% 0

Sep 28

SCYX received $19 million in non-dilutive funding from BARDA for the development of SCY-247, with the option to extend to $214 million.
The funding covers some research and development costs for free and was announced as a significant catalyst for the company.
SCYX has a legitimate catalyst with the BARDA contract, and may be a delayed runner, but some investors are concerned about the stock's price movement despite the positive news.

Generated by AI

Sentiment

Of the messages about SCYX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +20.95	80% -20	80.53% -14.71	83.17% +20.96
Bearish	0% -20.95	20% new	19.47% +14.71	16.83% -20.96

Bullish· Nov 20

$SCYX has a strong potential for a significant price increase, potentially reaching $7 per share, driven by its oversold status and upcoming milestones.
The company's FDA application and receipt of $145 million from Merck are expected to be major catalysts for its growth, with some predictions suggesting a price of $1.20 or higher.
With a strong cash position of $33 million, SCYX is well-positioned to capitalize on its upcoming milestones, including the potential launch of its product in the Chinese market, which could drive the stock price to $1.10 or higher.

Bearish· Sep 28

The bio market is "fucked" with shorts heavily hammering every stock that moves, including SCYX.
Despite recent positive news, including a huge Barda contract, the stock price is expected to go down due to the overall market conditions.
The stock price is struggling to find support, with multiple attempts to break through resistance levels at $5 and $4.80.

Generated by AI

Topics

Of the messages about SCYX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	61.1%
Technical Analysis	0%	0%	0%	15.01%
Analysts	0%	0%	0%	10.15%
Earnings	0%	0%	0%	2.33%
Macro	0%	0%	0%	9.51%
Controversies	0%	0%	0%	1.9%

Earnings· Aug 9

SCYNEXIS, Inc. (SCYX) reports earnings with an EPS of $0.23, missing estimates.
SCYX's earnings announcement comes with a reported EPS of $0.23.
SCYX's earnings miss estimates, with a reported EPS of $0.23.

Analysts· Oct 20

H.C. Wainwright initiated coverage of SCYNEXIS ($SCYX) with a "buy" rating and $14 price target.
SCYNEXIS ($SCYX) was initiated with a buy at H.C. Wainwright with a $14 price target.
H.C. Wainwright analyst Corey Davis initiated coverage of SCYNEXIS ($SCYX) with a "buy" rating and $14 price target.

Announcements· Sep 28

SCYNEXIS, Inc. (SCYX) has been awarded a BARDA contract providing up to $214 million in non-dilutive funding for the development of SCY-247.
The initial base of the contract is about $18.5 million, and the funding may extend up to 10 years to cover development through NDA for two indications.
SCY-247 has been granted FDA Orphan drug designation, and the company's market capitalization is currently lower than its cash reserves, with a market cap of $42 million.

Technical Analysis· Jan 6

SCYNEXIS, Inc. (SCYX) has been initiated with an Overweight rating and a $30 price target by Cantor Fitzgerald.
The stock is at a critical resistance level, with potential to break through and reach its next major level of resistance at $7.80, $8.08, or $8.44.
A bullish trend is indicated by a fibo chart, suggesting a price target of $9.66 based on the chart's analysis.

Generated by AI

Community

Of the messages about SCYX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	20.48%	20.37%	43.56%
Newcomers	100%	79.52%	79.63%	56.44%

Regulars· Sep 28

SCYX received a BARDA contract providing up to $214 million in non-dilutive funding for the development of SCY-247, a potential game-changer for the company's financials.
The regulars are cautiously optimistic about SCYX's prospects, with some considering it a "delayed runner" that may take time to move, but with a legitimate catalyst in the BARDA funding.
SCYX's market capitalization is relatively small at $42 million, which may be undervalued given the company's recent news and the potential for future growth with the BARDA funding.

Newcomers· Sep 28

The newcomers are focused on the recent BARDA contract worth up to $214 million for SCYNEXIS, Inc.'s SCY-247 program, which could lead to a price increase of at least 24 cents per share.
Many are confused by the unusual price movement, with over 7.5 million shares traded but only a slight price increase, and are speculating about potential institutional acquisitions.
The newcomers are also concerned about the short-selling activity, with some calling the bio market "terrible" and expressing frustration that the company's strong fundamentals, including a cash position until 2029, are not being reflected in the stock price.

Generated by AI

News

Also Discussed

Investors talking about SCYX also mention

#	Name	Attention
1	CDTX - Cidara Therapeutics, Inc.	——
2	Aurinia Pharmaceuticals IncAUPH	0.01%+0.01
3	TCON - TRACON Pharmaceuticals, Inc.	——
4	PRTK - Paratek Pharmaceuticals, Inc.	——
5	DRRX - DURECT Corporation	——
6	MRNS - Marinus Pharmaceuticals, Inc.	——
7	Ocular Therapeutix, Inc.OCUL	0.02%-0.04
8	Lipocine Inc.LPCN	0%new
9	BDSI - BioDelivery Sciences International, Inc.	——
10	ADVM - Adverum Biotechnologies, Inc.	——

SCYNEXIS, Inc. Common Stock

Healthcare
Drug Manufacturers - Specialty & Generic

SCYNEXIS, Inc. Common Stock represents the equity of SCYNEXIS, Inc., a biotechnology company focused on developing therapies for difficult-to-treat and drug-resistant fungal infections as well as certain severe rare diseases. The company markets BREXAFEMME for vulvovaginal candidiasis and recurrent vulvovaginal candidiasis, while also advancing investigational candidates such as ibrexafungerp and SCY-247 for broader antifungal and infectious disease applications. SCYNEXIS works across drug development, commercialization, and collaborative partnerships to support the treatment and prevention of serious infections with limited options. Headquartered in Jersey City, New Jersey, the company operates in the specialty pharmaceuticals segment of the healthcare market and serves as a focused biotechnology platform centered on anti-infective innovation.

Website

Location

1 Evertrust Plaza

Jersey City, NJ, 07302-6548

United States

Social

What share of all stock conversation is about SCYX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.02	0% +0	0% +0	0% 0

Sep 28

SCYX received $19 million in non-dilutive funding from BARDA for the development of SCY-247, with the option to extend to $214 million.
The funding covers some research and development costs for free and was announced as a significant catalyst for the company.
SCYX has a legitimate catalyst with the BARDA contract, and may be a delayed runner, but some investors are concerned about the stock's price movement despite the positive news.

Generated by AI

Sentiment

Of the messages about SCYX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +20.95	80% -20	80.53% -14.71	83.17% +20.96
Bearish	0% -20.95	20% new	19.47% +14.71	16.83% -20.96

Bullish· Nov 20

$SCYX has a strong potential for a significant price increase, potentially reaching $7 per share, driven by its oversold status and upcoming milestones.
The company's FDA application and receipt of $145 million from Merck are expected to be major catalysts for its growth, with some predictions suggesting a price of $1.20 or higher.
With a strong cash position of $33 million, SCYX is well-positioned to capitalize on its upcoming milestones, including the potential launch of its product in the Chinese market, which could drive the stock price to $1.10 or higher.

Bearish· Sep 28

The bio market is "fucked" with shorts heavily hammering every stock that moves, including SCYX.
Despite recent positive news, including a huge Barda contract, the stock price is expected to go down due to the overall market conditions.
The stock price is struggling to find support, with multiple attempts to break through resistance levels at $5 and $4.80.

Generated by AI

Topics

Of the messages about SCYX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	61.1%
Technical Analysis	0%	0%	0%	15.01%
Analysts	0%	0%	0%	10.15%
Earnings	0%	0%	0%	2.33%
Macro	0%	0%	0%	9.51%
Controversies	0%	0%	0%	1.9%

Earnings· Aug 9

SCYNEXIS, Inc. (SCYX) reports earnings with an EPS of $0.23, missing estimates.
SCYX's earnings announcement comes with a reported EPS of $0.23.
SCYX's earnings miss estimates, with a reported EPS of $0.23.

Analysts· Oct 20

H.C. Wainwright initiated coverage of SCYNEXIS ($SCYX) with a "buy" rating and $14 price target.
SCYNEXIS ($SCYX) was initiated with a buy at H.C. Wainwright with a $14 price target.
H.C. Wainwright analyst Corey Davis initiated coverage of SCYNEXIS ($SCYX) with a "buy" rating and $14 price target.

Announcements· Sep 28

SCYNEXIS, Inc. (SCYX) has been awarded a BARDA contract providing up to $214 million in non-dilutive funding for the development of SCY-247.
The initial base of the contract is about $18.5 million, and the funding may extend up to 10 years to cover development through NDA for two indications.
SCY-247 has been granted FDA Orphan drug designation, and the company's market capitalization is currently lower than its cash reserves, with a market cap of $42 million.

Technical Analysis· Jan 6

SCYNEXIS, Inc. (SCYX) has been initiated with an Overweight rating and a $30 price target by Cantor Fitzgerald.
The stock is at a critical resistance level, with potential to break through and reach its next major level of resistance at $7.80, $8.08, or $8.44.
A bullish trend is indicated by a fibo chart, suggesting a price target of $9.66 based on the chart's analysis.

Generated by AI

Community

Of the messages about SCYX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	20.48%	20.37%	43.56%
Newcomers	100%	79.52%	79.63%	56.44%

Regulars· Sep 28

SCYX received a BARDA contract providing up to $214 million in non-dilutive funding for the development of SCY-247, a potential game-changer for the company's financials.
The regulars are cautiously optimistic about SCYX's prospects, with some considering it a "delayed runner" that may take time to move, but with a legitimate catalyst in the BARDA funding.
SCYX's market capitalization is relatively small at $42 million, which may be undervalued given the company's recent news and the potential for future growth with the BARDA funding.

Newcomers· Sep 28

The newcomers are focused on the recent BARDA contract worth up to $214 million for SCYNEXIS, Inc.'s SCY-247 program, which could lead to a price increase of at least 24 cents per share.
Many are confused by the unusual price movement, with over 7.5 million shares traded but only a slight price increase, and are speculating about potential institutional acquisitions.
The newcomers are also concerned about the short-selling activity, with some calling the bio market "terrible" and expressing frustration that the company's strong fundamentals, including a cash position until 2029, are not being reflected in the stock price.

Generated by AI

SCYNEXIS

Social

Sep 28

Bullish· Nov 20

Bearish· Sep 28

Earnings· Aug 9

Analysts· Oct 20

Announcements· Sep 28

Technical Analysis· Jan 6

Regulars· Sep 28

Newcomers· Sep 28

Scynexis stock surges on $214M BARDA contract for SCY-247

SCYNEXIS secures BARDA contract for antifungal development

Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract

Why is Scynexis stock surging today?

Scynexis appoints Steven Burke to board of directors

Scynexis appoints Todd Minga as senior VP of R&D

Also Discussed

SCYNEXIS, Inc. Common Stock

Company Information

Location

Scynexis stock surges on $214M BARDA contract for SCY-247

SCYNEXIS secures BARDA contract for antifungal development

Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract

Why is Scynexis stock surging today?

Scynexis appoints Steven Burke to board of directors

Scynexis appoints Todd Minga as senior VP of R&D

Also Discussed

Social

Sep 28

Bullish· Nov 20

Bearish· Sep 28

Earnings· Aug 9

Analysts· Oct 20

Announcements· Sep 28

Technical Analysis· Jan 6

Regulars· Sep 28

Newcomers· Sep 28